A photo of Nikolai Timchenko.

Head of Liver Tumor Biology, Liver Tumor Program

Professor, UC Department of Surgery


Biography & Affiliation


Nikolai A. Timchenko, PhD, came to Cincinnati Children’s Hospital Medical Center in June of 2014 from Baylor College of Medicine (BCM), where he was a professor of pathology and was working in the Huffington Center on aging.

Dr. Timchenko obtained his PhD in the Institute of Experimental Medicine in St. Petersburg, Russia in the field of liver biology and molecular genetics. After moving to the US, Dr. Timchenko worked at BCM as an assistant professor, associate professor, and full professor until 2014.

He is currently a professor in the Division of General and Thoracic Surgery at Cincinnati Children's within the UC Department of Surgery. Dr. Timchenko is also the director of the Liver Tumor Program. He investigates mechanisms of liver cancer in children and adults, mechanisms of NAFLD, and mechanisms of age-associated diseases.

Dr. Timchenko is a member of the Digestive Health Center (Cincinnati Children's) and a professor in the Department of Surgery at the University of Cincinnati.

Academic Affiliation

Professor, UC Department of Surgery


General and Thoracic Surgery, Fibrosis


PhD: Institute of Experimental Medicine, St. Petersburg, Russia.

Training: Post-Doc Fellow, Department of Pathology, Baylor College of Medicine, Houston, TX.


Correction of glycogen synthase kinase 3β in myotonic dystrophy 1 reduces the mutant RNA and improves postnatal survival of DMSXL mice. Wang, M; Weng, W; Stock, L; Lindquist, D; Martinez, A; Gourdon, G; Timchenko, N; Snape, M; Timchenko, L. Molecular and Cellular Biology. 2019; 39.

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease. Cast, A; Kumbaji, M; D'Souza, A; Rodriguez, K; Gupta, A; Karns, R; Timchenko, L; Timchenko, N. Hepatology Communications. 2019; 3:1036-1049.

NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. Khanal, T; Leung, Y; Jiang, W; Timchenko, N; Ho, S; Kim, K. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019; 33:8335-8348.

PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma. Valanejad, L; Cast, A; Wright, M; Bissig, K; Karns, R; Weirauch, MT; Timchenko, N. Communications Biology. 2018; 1.

Correction of aging phenotype in the liver. Rodriguez, K; Cast, A; Timchenko, NA. Aging-US. 2018; 10:1795-1796.

Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBP alpha-p300 Axis. Nguyen, P; Valanejad, L; Cast, A; Wright, M; Garcia, JM; El-Serag, HB; Karns, R; Timchenko, NA. Cell Reports. 2018; 24:1597-1609.

Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy. Wei, C; Stock, L; Schneider-Gold, C; Sommer, C; Timchenko, NA; Timchenko, L. Molecular and Cellular Biology. 2018; 38.

C/EBP-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Cast, A; Valanejad, L; Wright, M; Nguyen, P; Gupta, A; Zhu, L; Shin, S; Timchenko, N. Hepatology. 2018; 67:1857-1871.

Correction of GSK3 beta at young age prevents muscle pathology in mice with myotonic dystrophy type 1. Wei, C; Stock, L; Valanejad, L; Zalewski, ZA; Karns, R; Puymirat, J; Nelson, D; Witte, D; Woodgett, J; Timchenko, NA; et al. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018; 32:2073-2085.

Mitochondrial and anabolic pathways in hepatocellular carcinoma. Timchenko, NA. Hepatology. 2018; 67:823-825.